Picard Medical / SynCardia Highlight Second Successful Total Artificial Heart Bridge to Transplant at UCSF Health
MWN-AI** Summary
**Picard Medical Highlights Second Successful Total Artificial Heart Bridge to Transplant at UCSF Health**
On March 19, 2026, Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, announced a significant milestone in cardiac care: the successful bridging of a patient with advanced biventricular heart failure to heart transplantation using the SynCardia Total Artificial Heart at UCSF Health. The patient, a male in his twenties, received the implant on November 15, 2025, which provided essential circulatory support while he awaited a donor organ.
After 119 days of reliance on the SynCardia device, the patient underwent a heart transplant on March 14, 2026, marking the second successful transplantation out of five total cases at UCSF Health utilizing this technology. Dr. Amy G. Fiedler, the Surgical Director at UCSF, expressed satisfaction with the procedure and the partnership with SynCardia, emphasizing their commitment to helping critically ill patients.
The SynCardia Total Artificial Heart stands out as the first artificial heart to receive FDA and Health Canada approval, and it remains the sole device of its kind commercially available in the U.S. and Canada. With over 2,100 implants conducted across 27 countries, it has established itself as the most extensively studied artificial heart globally.
Patrick NJ Schnegelsberg, CEO of Picard Medical, praised the clinical teams involved in this case and acknowledged the increasing adoption of this life-saving technology in prominent transplant centers. He highlighted the growing need for advanced mechanical circulatory support for those suffering from end-stage heart failure.
For further information, visit Picard Medical’s website or their SEC filings.
MWN-AI** Analysis
On March 19, 2026, Picard Medical, Inc. (PMI), the parent company of SynCardia Systems LLC, achieved a significant milestone with news of the successful bridging of a patient to heart transplantation via its SynCardia Total Artificial Heart (TAH) at UCSF Health. This is the second of five planned cases indicating that SynCardia's technology is gaining traction in the critical area of advanced heart failure management.
Investors should take note of several factors that could influence PMI's market performance moving forward. The innovative application of the TAH is vital as it addresses the urgent need for mechanical circulatory support among patients with end-stage heart failure, a demographic that is expanding globally due to rising cardiovascular diseases.
The successful implementation of TAHs in complex cases bodes well for increasing acceptance and adoption at major transplant centers. Following the implementation of advanced therapies aligns PMI with the trending focus on personalized precision medicine, positioning it to capture additional market share in the burgeoning cardiac rehabilitation industry.
As the only approved heart device in both the U.S. and Canada, PMI stands out in terms of exclusivity. The recent successful procedures highlight the efficacy of the SynCardia TAH, potentially driving demand from hospitals looking to incorporate cutting-edge solutions into their treatment paradigms.
However, investors should remain cautiously optimistic, as the company is subject to regulatory and operational risks inherent in the medical device industry. Future financial performance will depend on the successful scaling of operations and the ability to navigate the complexities of healthcare regulations.
Overall, PMI's current trajectory, complemented by recent clinical successes, makes it an attractive consideration for investors looking to establish a position in the medical device sector focused on cardiac innovations. Regular monitoring of clinical updates and regulatory developments will be essential for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TUCSON, Ariz., March 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today highlighted a case reported by UCSF Health in which a patient in his twenties with advanced biventricular heart failure was successfully bridged to heart transplantation using the SynCardia Total Artificial Heart. The patient, a male in his twenties, received the SynCardia Total Artificial Heart on November 15, 2025 to restore full circulatory support while awaiting a donor heart. After 119 days of support with the device, the patient underwent a successful heart transplant on March 14, 2026.
This case represents the second of five patients at UCSF Health who have been successfully bridged to transplantation using the SynCardia Total Artificial Heart, highlighting the role of total artificial heart therapy in supporting patients with advanced biventricular heart failure while they await a donor organ.
“We are pleased to have performed our second successful redo sternotomy, total artificial heart explant and heart transplant at UCSF and are happy to report that the patient is recovering well,” said Amy G. Fiedler, MD, Associate Professor of Cardiac Surgery and Surgical Director of Heart Transplantation and Mechanical Circulatory Support at the University of California San Francisco. “Our program values its partnership with SynCardia and the ability to bridge some of the sickest patients to successful heart transplantation.”
Cases such as this demonstrate the growing experience with total artificial heart therapy at leading transplant centers such as UCSF Health.
“We congratulate the physicians and care teams involved and are proud the SynCardia Total Artificial Heart provided critical time while this patient awaited transplantation. Adoption at leading transplant centers reflects the growing need for advanced mechanical circulatory support for patients with end-stage heart failure,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
How does the recent success of the SynCardia Total Artificial Heart in bridging patients to transplantation impact the market outlook for Picard Medical Inc. PMI in the rapidly evolving field of mechanical circulatory support?
What strategies is Picard Medical Inc. PMI implementing to increase adoption rates of the SynCardia Total Artificial Heart across more transplant centers globally?
How does Picard Medical Inc. PMI plan to capitalize on the growing experience and success from cases like the one reported by UCSF Health to boost investor confidence and market presence?
Given the competitive landscape in cardiovascular technologies, what unique advantages does Picard Medical Inc. PMI believe the SynCardia Total Artificial Heart offers over potential alternatives?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
-9.29% G/L:
$0.4558 Last:
1,208,358 Volume:
$0.46 Open:
